Loading resource…
BMJ
The guideline addresses the benefits and harms of SGLT-2 inhibitors for adults living with CKD, highlighting their potential to slow disease progression and improve long-term prognosis. It emphasizes the need for stratified treatment recommendations based on the risk of CKD progression and complications. The guideline was developed by an international panel including various healthcare professionals and patient partners, ensuring a comprehensive approach to treatment recommendations.
No account needed